Study of inhibition of B16F10 melanoma growth in mice by landomycin A in comparison to doxorubicin

• Main Authors: L. V. Lehka, R. R. Panchuk, N. R. Skorokhyd, Yu. S. Kozak, J. Rohr, R. S. Stoika
• Format: Article
• Language: English
• Published: Львівський національний університет імені Івана Франка 2016-03-01
• Series: Біологічні студії
• Subjects: landomycin A; melanoma; tumor volume; oxidative therapy
• Online Access: http://publications.lnu.edu.ua/journals/index.php/biology/article/view/62

Landomycin A is a new antibiotic of angucycline group with antineoplastic activity against tumor cells of different origin. In this work, we investigated the effects of landomycin A on the growth of B16F10 mouse melanoma. It was elucidated that studied antibiotic possessed a significant dose-dependent cytotoxic activity against these melanoma cells in vitro, and its LC50 = 2 µM was 5 times lower than that of the doxorubicin, anticancer drug widely used for treatment of solid tumors. Landomycin A at concentration of 10 mg/kg body weight did not cause pathological changes, mortality or general toxic symptoms in intact mice of C57black/6 line. No significant changes in the body weight and hematological parameters of animals treated with landomycin A as compared to the control group were observed. While B16F10 melanoma maintained rapid growth in vivo with a continual increase in tumor volume, landomycin A effectively inhibi­ted tumor growth without a marked myelosuppressive effects or cardio- and hepatotoxicity that are characteristic for doxorubicin action. These results suggest a perspective of landomycin A application in chemotherapy of malignant tumors.